You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
Title |
Treatment for primary hypothyroidism: current approaches and future possibilities
|
---|---|
Published in |
Drug Design, Development and Therapy, December 2011
|
DOI | 10.2147/dddt.s12894 |
Pubmed ID | |
Authors |
Ali J Chakera, Simon HS Pearce, Bijay Vaidya |
Abstract |
Primary hypothyroidism is the most common endocrine disease. Although the diagnosis and treatment of hypothyroidism is often considered simple, there are large numbers of people with this condition who are suboptimally treated. Even in those people with hypothyroidism who are biochemically euthyroid on levothyroxine replacement there is a significant proportion who report poorer quality of life. This review explores the historical and current treatment options for hypothyroidism, reasons for and potential solutions to suboptimal treatment, and future possibilities in the treatment of hypothyroidism. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 2 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 352 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 3 | <1% |
India | 1 | <1% |
Canada | 1 | <1% |
Unknown | 347 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 96 | 27% |
Student > Master | 47 | 13% |
Student > Postgraduate | 34 | 10% |
Researcher | 23 | 7% |
Student > Doctoral Student | 21 | 6% |
Other | 51 | 14% |
Unknown | 80 | 23% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 110 | 31% |
Agricultural and Biological Sciences | 48 | 14% |
Biochemistry, Genetics and Molecular Biology | 28 | 8% |
Nursing and Health Professions | 28 | 8% |
Pharmacology, Toxicology and Pharmaceutical Science | 17 | 5% |
Other | 33 | 9% |
Unknown | 88 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 22. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 December 2022.
All research outputs
#1,746,249
of 25,541,640 outputs
Outputs from Drug Design, Development and Therapy
#77
of 2,273 outputs
Outputs of similar age
#11,404
of 246,826 outputs
Outputs of similar age from Drug Design, Development and Therapy
#2
of 4 outputs
Altmetric has tracked 25,541,640 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,273 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 246,826 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.